- Details
- Hits: 1158
The Association Between Tobacco and Cannabis Use and the Age of Onset of Depression and Anxiety Symptoms Among Adolescents and Young Adults
Abstract
Purpose: No studies have prospectively explored the association between the use of tobacco or cannabis use and the age of onset of depressive or anxiety symptoms, and no studies have identified the peak ages and ranges of onset of these symptoms among tobacco and/or cannabis users.
Methods: This is a secondary analysis of Texas Adolescent Tobacco and Marketing Surveillance System data, waves 9-14 (2019-20121). Participants were in 10th grade, 12 th grade, and two years post-high school (HS) at baseline (Wave 9). Interval-censoring multivariable Cox proportional hazards models were fit to assess differences in the estimated age of onset of depression and anxiety by tobacco and cannabis use while adjusting for covariates.
Results: We found that lifetime or ever cigarette, e-cigarette, and cannabis use had an increased risk of an earlier age of onset of depressive and anxiety symptoms across the three cohorts, and the youngest cohort was the most differentially impacted by substance use. Between ages 18 to 19 years in the 10th-grade cohort, between ages 20 to 21 years in the 12th-grade cohort, and between ages 22 to 23 years in the post-HS cohort, the estimated hazard function (or cumulative incidence) for reporting depressive and anxiety symptoms almost doubled among lifetime cigarette, e-cigarette, and cannabis users.
Conclusions: Tobacco and cannabis users should be screened for mental health problems at an earlier age, especially those aged 18 years and younger, and provided with age- and culturally-appropriate resources to prevent or delay the onset of anxiety and/or depression symptoms.
Implications: The study's findings indicate that tobacco and cannabis use is directly linked to the early onset of depressive and anxiety symptoms among youth. This highlights the significance of early screening and substance use interventions, particularly for youth aged 18 years and younger, as they are disproportionately affected by both substance use and mental health problems. School-based interventions that are age- and culturally appropriate hold promise as they enable youth to seek professional help early, and in a supportive environment. Intervening early in substance shows promise in reducing the likelihood of developing mental health problems at a young age. (Source:National Library of Medicine April 2023)
Also see
- All Young Cannabis Users Face Risk of Psychosis
- Smoking cannabis in your teens IS linked to depression in later life: Major study reveals drug 'damages children's brains' and half a MILLION adults could avoid mental-health disorder if they had turned down marijuana
- CANNABIS USERS AT 'MUCH HIGHER' RISK OF DEVELOPING POOR MENTAL HEALTH
- Details
- Hits: 896
Summary: The prevalence of cannabis use in women of childbearing age is increasing drastically, likely related to increased legalization. Cannabis use during pregnancy is likely associated with preterm birth, low birth weight, and long-term neuropsychiatric outcomes, although data have significant limitations. Providers should screen for cannabis use and CUD regularly and counsel women about the known and unknown data regarding outcomes. It is important to identify co-occurring mental health disorders (Source: Advances in Psychiatry & Behavioural Health – 2023)
Also see
- Details
- Hits: 979
The prevalence of cannabis use is rising among the US population.1 As cannabis continues to be legalized throughout the USA, people are turning to the internet and social media for information about its potential health benefits.2,3 In this study, we characterize internet claims about the health benefits of cannabis use in the lay press and evaluate the evidence base supporting those claims.
Social contagion based experimentation with cannabis is incredibly risky, especially when patients turn to ‘Social Media Pot Physicians’ The Journal of General Internal Medicine found that fewer than 5% of claims made for cannabis on the internet were true; more than 80% were patently false. (Source: Internet Claims on the Health Benefits of Cannabis Use - PMC (nih.gov)
Also see
- Details
- Hits: 943
Research Reveals…Of the 30 melatonin gummy brands meeting the inclusion criteria, 4 were unavailable for purchase and 1 did not contain “melatonin” on the actual label; therefore, 25 products were analyzed. One product did not contain detectable levels of melatonin but did contain 31.3 mg of CBD. In the remaining products, the quantity of melatonin ranged from 1.3 mg to 13.1 mg per serving size (Table). In products that contained melatonin, the actual quantity of melatonin ranged from 74% to 347% of the labeled quantity. Twenty-two of 25 products (88%) were inaccurately labeled, and only 3 products (12%) contained a quantity of melatonin that was within ±10% of the declared quantity. Five products declared CBD as an ingredient, and the quantity of CBD ranged from 10.6 mg to 31.3 mg per serving. The actual quantity of CBD ranged from 104% to 118% of the labeled quantity. Serotonin was not detected in any product.
(Non-clinically trialled and harmful Cannabinoid products are being unleashed into communities because of the ‘vote for medicine’ model – Next to no science – no credibility – no care for harms done!)